Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NON-ALCOHOLIC STEATOHEPATITIS AND HAEMOSTASIS

The mega-importance of de novo lipogenesis in platelet production

Nature Metabolism volume 2, pages 999–1000 (2020)Cite this article

Subjects

Aberrant upregulation of de novo lipogenesis is linked to non-alcoholic fatty liver disease and some cancers. A new study by Kelly et al. finds that inhibiting this pathway by blocking the activity of acetyl-CoA carboxylase has unexpected effects on the formation of platelets from megakaryocytes within the bone marrow of primates but not rodents, thus suggesting clinical implications for de novo lipogenesis inhibitors as a new class of therapeutics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic outlining platelet production and the proposed mechanisms through which DNL inhibitors inhibit this process.

References

  1. Softic, S., Cohen, D. E. & Kahn, C. R. Dig. Dis. Sci. 61, 1282–1293 (2016).

    Article  CAS  Google Scholar 

  2. Arnold, D. M., Nazi, I. & Kelton, J. G. Expert Opin. Investig. Drugs 18, 805–819 (2009).

    Article  CAS  Google Scholar 

  3. Sebo, Z. L. et al. Endocr. Rev. 40, 1187–1206 (2019).

    Article  Google Scholar 

  4. Valet, C. et al. Cell Rep. 32, 107875 (2020).

    Article  CAS  Google Scholar 

  5. Siddiqui, N. F., Shabrani, N. C., Kale, V. P. & Limaye, L. S. Cytotherapy 13, 114–128 (2011).

    Article  CAS  Google Scholar 

  6. Kelly, K. L. et al. Nat. Metab. https://doi.org/10.1038/s42255-020-00272-9 (2020).

  7. Lepropre, S. et al. Blood 132, 1180–1192 (2018).

    Article  CAS  Google Scholar 

  8. Bashour, F. N., Teran, J. C. & Mullen, K. D. Am. J. Gastroenterol. 95, 2936–2939 (2000).

    Article  CAS  Google Scholar 

  9. Lally, J. S. V. et al. Cell Metab. 29, 174–182 (2019).

    Article  CAS  Google Scholar 

  10. Pinkosky, S. L. et al. Nat. Commun. 7, 13457 (2016).

    Article  CAS  Google Scholar 

  11. Ray, K. K. et al. N. Engl. J. Med. 380, 1022–1032 (2019).

    Article  CAS  Google Scholar 

  12. Horn, P. & Newsome, P. N. Expert Opin. Ther. Targets 24, 175–186 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Ishac Nazy, Donald M. Arnold & Gregory R. Steinberg

  2. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada

    Ishac Nazy & Gregory R. Steinberg

  3. Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada

    Ishac Nazy & Donald M. Arnold

  4. Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada

    Gregory R. Steinberg

Authors
  1. Ishac Nazy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald M. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory R. Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory R. Steinberg.

Ethics declarations

Competing interests

G.R.S. is a cofounder and shareholder of Espervita Therapeutics. McMaster University has received funding from Espervita Therapeutics, Esperion Therapeutics and Poxel Pharma for research conducted by the laboratory of G.R.S. G.R.S. has received consulting or speaking fees from Allysta Pharmaceuticals, Eli Lilly, Esperion Therapeutics, Merck, Poxel Pharma and Takeda. I.N. and D.M.A. have no conflicts of interest to report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nazy, I., Arnold, D.M. & Steinberg, G.R. The mega-importance of de novo lipogenesis in platelet production. Nat Metab 2, 999–1000 (2020). https://doi.org/10.1038/s42255-020-00282-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-020-00282-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research